Drug Profile
Research programme: proteases - Bayer Schering Pharma/Pfizer
Latest Information Update: 23 Mar 2010
Price :
$50
*
At a glance
- Originator Direvo Biotech
- Developer Bayer Schering Pharma; Pfizer
- Class Peptide hydrolases
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 30 Sep 2008 DIREVO Biotech has been acquired and merged into Bayer Schering Pharma
- 12 Nov 2007 Early research in Undefined indication in Germany (unspecified route)
- 12 Nov 2007 Early research in Undefined indication in USA (unspecified route)